Zynerba Pharmaceuticals Inc. (ZYNE) Shares Up 4.1%
Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) shot up 4.1% during trading on Thursday . The stock traded as high as $10.19 and last traded at $9.91, with a volume of 143,671 shares trading hands. The stock had previously closed at $9.52.
ZYNE has been the topic of several analyst reports. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Zynerba Pharmaceuticals in a report on Tuesday, May 3rd. Zacks Investment Research upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.50 price objective on the stock in a report on Tuesday, July 19th. Canaccord Genuity restated a “buy” rating on shares of Zynerba Pharmaceuticals in a report on Monday, April 18th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $42.00 price objective on shares of Zynerba Pharmaceuticals in a report on Tuesday, July 26th. Six analysts have rated the stock with a buy rating, Zynerba Pharmaceuticals has an average rating of “Buy” and an average target price of $28.58.
The stock’s market capitalization is $91.16 million. The firm’s 50 day moving average price is $7.98 and its 200 day moving average price is $8.14.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its earnings results on Thursday, August 11th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.18. Analysts predict that Zynerba Pharmaceuticals Inc. will post ($2.37) earnings per share for the current fiscal year.
Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications, including refractory epilepsy, Fragile X syndrome (FXS), osteoarthritis (OA), fibromyalgia and peripheral neuropathic pain.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.